Partner with us:
We believe great science comes from working together.
Focus on R&D:
Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.
Recent News
- April 28, 2022
- Asahi Kasei Pharma filed for provisional injunctions against infringement of patent rights of “TeriboneTM Injection”
- March 31, 2022
- Asahi Kasei Pharma signs exclusive license agreement with VectivBio to develop and commercialize next-generation GLP-2 analog peptide apraglutide in Japan
- March 28, 2022
- Start of Japan-US international phase 1 study of ART-123 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)
- October 7, 2021
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- September 30, 2021
- Asahi Kasei Pharma obtains exclusive option for AGN1 LOEP Hip Kit
- July 19, 2021
- Sanofi and Asahi Kasei Pharma execute a marketing license agreement to transfer sales right in Japan for Plaquenil® Tablets 200 mg, an immunomodulator
- January 29, 2021
- Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
- October 13, 2020
- Asahi Kasei Pharma to solicit proposals for drug discovery research
